- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07938840
Opioid-Free Total Shoulder With Suzetrigine
Opioid-Free Postoperative Analgesia With Suzetrigine Following Total Shoulder Arthroplasty: A Prospective Randomized Controlled Noninferiority Trial
This prospective, randomized, unblinded, controlled noninferiority study may benefit patients by determining whether an opioid-free postoperative analgesic pathway utilizing suzetrigine can provide adequate pain control following primary anatomic or reverse total shoulder arthroplasty compared with a standard opioid-containing pathway. If effective, this strategy may reduce or eliminate routine postoperative opioid use and associated adverse effects while maintaining patient satisfaction and adequate pain control. More broadly, this study will provide prospective data regarding the effectiveness and safety of suzetrigine following total shoulder arthroplasty and may help inform future opioid-free postoperative pain management protocols.
Study Overview
Status
Intervention / Treatment
Detailed Description
Objective 1: To determine whether an opioid-free postoperative analgesic pathway utilizing suzetrigine provides noninferior postoperative pain control at 24 hours following primary anatomic or reverse total shoulder arthroplasty compared with a standard opioid-containing postoperative analgesic pathway.
Hypothesis 1: Postoperative pain at 24 hours among patients randomized to the opioid-free suzetrigine pathway will be noninferior to postoperative pain among patients randomized to the standard opioid-containing pathway.
Objective 2: To compare postoperative opioid consumption, requirement for rescue opioid analgesia, time to first rescue opioid, postoperative pain scores, opioid-related adverse effects, and patient satisfaction between treatment groups.
Hypothesis 2: Patients randomized to the opioid-free suzetrigine pathway will have lower cumulative postoperative opioid consumption and reduced need for rescue opioid analgesia without clinically meaningful worsening of postoperative pain, or patient satisfaction.
Objective 3: To evaluate the safety profile of suzetrigine following total shoulder arthroplasty by characterizing adverse events, medication-related adverse effects, drug-drug interactions, treatment discontinuation, emergency department visits, unplanned readmissions, and reoperations.
Hypothesis 3: Patients randomized to the opioid-free suzetrigine pathway will have lower rates of opioid-related adverse events, including sedation, respiratory depression, nausea, and constipation, compared with patients randomized to the standard opioid-containing pathway.
Objective 4: To evaluate shoulder-specific functional outcomes and determine whether preoperative patient resilience is associated with postoperative pain control, opioid requirements, rescue opioid use, and patient satisfaction.
Hypothesis 4: Shoulder-specific patient-reported outcomes will be comparable between treatment groups. Greater preoperative resilience, as measured by the CD-RISC-10, will be associated with lower postoperative pain, reduced opioid consumption, decreased need for rescue opioid analgesia, and greater satisfaction with pain control.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Caleb J Michalek, BS
- Phone Number: 704-323-3698
- Email: caleb.michalek@orthocarolina.com
Study Contact Backup
- Name: Caleb Lifsey
- Phone Number: 704-323-2412
- Email: caleb.lifsey@orthocarolina.com
Study Locations
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- OrthoCarolina Research Institute
-
Principal Investigator:
- Nady Hamid, MD
-
Contact:
- Caleb J Michalek, BS
- Phone Number: 704-323-3698
- Email: caleb.michalek@orthocarolina.com
-
Contact:
- Caleb Lifsey
- Phone Number: 704-323-2412
- Email: caleb.lifsey@orthocarolina.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years
- Undergoing elective primary anatomic or reverse total shoulder arthroplasty
- English-speaking (for patient-reported outcome assessments)
Exclusion Criteria:
-
Revision arthroplasty procedures
-
Total shoulder arthroplasty performed for a fracture-related indication, including acute fractures and chronic fracture sequelae (e.g., malunion or nonunion)
-
History of chronic opioid use (defined as daily or near-daily use for ≥90 days preoperatively)
-
Contraindications to suzetrigine:
- Known allergy or hypersensitivity to suzetrigine
- Current use of strong CYP3A inhibitors (contraindicated per FDA labeling)
- Current use of strong or moderate CYP3A inducers (should be avoided per FDA labeling)
- Severe hepatic impairment (Child-Pugh Class C)
- Severe renal impairment (eGFR <15 mL/min/1.73 m²)
-
Pregnancy or breastfeeding
-
Inability to complete patient-reported outcome measures
-
Simultaneous bilateral arthroplasty
-
Unable or unwilling to provide informed consent or comply with study procedures
-
Total shoulder arthroplasty performed for an oncologic indication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard Opioid-Containing Pathway
Patients randomized to the control group will receive the standardized multimodal analgesic regimen outlined in Table 1, including postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. The non-opioid components of the multimodal analgesic regimen will be identical between treatment groups. |
Patients randomized to the intervention group will receive the same standardized multimodal analgesic regimen outlined in Table 2, with suzetrigine administered in place of postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. Rescue opioid analgesia will be available for inadequate pain control according to predefined rescue criteria. Suzetrigine will be administered according to the standardized study dosing protocol, with a 100 mg oral loading dose administered preoperatively, followed by 50 mg orally every 12 hours for 14 days. |
|
Experimental: Opioid-Free Suzetrigine Pathway
Patients randomized to the intervention group will receive the same standardized multimodal analgesic regimen outlined in Table 2, with suzetrigine administered in place of postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. Rescue opioid analgesia will be available for inadequate pain control according to predefined rescue criteria. Suzetrigine will be administered according to the standardized study dosing protocol, with a 100 mg oral loading dose administered preoperatively, followed by 50 mg orally every 12 hours for 14 days. |
Patients randomized to the control group will receive the standardized multimodal analgesic regimen outlined in Table 1, including postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. The non-opioid components of the multimodal analgesic regimen will be identical between treatment groups. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Numeric Rating Scale (NRS)
Time Frame: 24 hours post-surgery
|
The primary outcome will be postoperative pain measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain) at 24 hours following surgery. |
24 hours post-surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Numeric Rating Scale (NRS)
Time Frame: From enrollment to the end of treatment at 1 year
|
The primary outcome will be postoperative pain measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain) |
From enrollment to the end of treatment at 1 year
|
|
Morphine Milligram Equivalents (MME)
Time Frame: 24 hours postoperative
|
Cumulative opioid consumption converted to MME |
24 hours postoperative
|
|
Morphine Milligram Equivalents (MME)
Time Frame: 48 hours postoperative
|
Cumulative opioid consumption converted to MME |
48 hours postoperative
|
|
Rescue opioid analgesia
Time Frame: From enrollment to the end of treatment at 1 year
|
Requirement for rescue opioid analgesia (yes/no) |
From enrollment to the end of treatment at 1 year
|
|
Patient satisfaction with overall pain control
Time Frame: From enrollment to the end of treatment at 1 year
|
Patient satisfaction with overall pain control, measured on a scale of 0-10 with 0 being less satisfied and 10 being completely satisfied. |
From enrollment to the end of treatment at 1 year
|
|
Hospital length of stay
Time Frame: At the time of surgery treatment.
|
Time spent in hospital |
At the time of surgery treatment.
|
|
American Shoulder and Elbow Surgeons (ASES) Shoulder Score
Time Frame: From enrollment to the end of treatment at 1 year
|
The American Shoulder and Elbow Surgeons Shoulder Score (ASES) was designed to assess the condition of the shoulder, regardless of disease pathology. The ASES is a composite instrument, requiring both a physician assessment and a patient-completed portion; however, it is commonly presented as solely the patient-reported survey. This includes a section on pain (7 items) and a section on activities of daily living (10 items). Scores range from 0 to 100 with a score of 0 indicating a worse shoulder condition and 100 indicating a better shoulder condition. |
From enrollment to the end of treatment at 1 year
|
|
Single Assessment Numeric Evaluation (SANE)
Time Frame: From enrollment to the end of treatment at 1 year
|
Patients are asked: "How would you rate your shoulder today as a percentage of normal (0% to 100% scale, with 100% being a completely normal shoulder)?" |
From enrollment to the end of treatment at 1 year
|
|
Simple Shoulder Test (SST)
Time Frame: From enrollment to the end of treatment at 1 year
|
Self-reported questionnaire that evaluates shoulder function, comfort, and strength through simple "yes" or "no" questions that result in 0% (worst function) to 100% (best function) score. |
From enrollment to the end of treatment at 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nady Hamid, MD, OrthoCarolina Research Institute, Inc.
Publications and helpful links
General Publications
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.
- Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013 Apr;33(4):383-91. doi: 10.1002/phar.1223.
- American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012 Feb;116(2):248-73. doi: 10.1097/ALN.0b013e31823c1030. No abstract available.
- Sloan M, Premkumar A, Sheth NP. Projected Volume of Primary Total Joint Arthroplasty in the U.S., 2014 to 2030. J Bone Joint Surg Am. 2018 Sep 5;100(17):1455-1460. doi: 10.2106/JBJS.17.01617.
- Vadivelu N, Kai AM, Kodumudi V, Sramcik J, Kaye AD. The Opioid Crisis: a Comprehensive Overview. Curr Pain Headache Rep. 2018 Feb 23;22(3):16. doi: 10.1007/s11916-018-0670-z.
- Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, Oswald J, Swisher MW, Tian S, Miao X, Correll DJ, Negulescu P, Bozic C, Weiner SG. Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025 Jun 1;142(6):1085-1099. doi: 10.1097/ALN.0000000000005460. Epub 2025 Mar 21.
- Wylde V, Beswick A, Bruce J, Blom A, Howells N, Gooberman-Hill R. Chronic pain after total knee arthroplasty. EFORT Open Rev. 2018 Aug 16;3(8):461-470. doi: 10.1302/2058-5241.3.180004. eCollection 2018 Aug.
- Klein B, Faridi A, von Tempelhoff GF, Heilmann L, Mittermayer C, Rath W. A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Thromb Res. 2002 Dec 15;108(5-6):291-6. doi: 10.1016/s0049-3848(03)00094-x.
- Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2013 Jan;14(1):49-62. doi: 10.1038/nrn3404. Epub 2012 Dec 12.
- Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, Estacion M, Derjean D, Waxman SG, Layton G, Gunn K, Tate S; study investigators. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 2017 Apr;16(4):291-300. doi: 10.1016/S1474-4422(17)30005-4. Epub 2017 Feb 17.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Diseases
- Musculoskeletal Diseases
- Pathologic Processes
- Necrosis
- Pathological Conditions, Signs and Symptoms
- Osteonecrosis
- Surgical Procedures, Operative
- Arthroplasty, Replacement
- Arthroplasty
- Orthopedic Procedures
- Plastic Surgery Procedures
- Prosthesis Implantation
- Arthroplasty, Replacement, Shoulder
Other Study ID Numbers
- SE001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.